Paul Rennert
@pdrworld.bsky.social
Biotech exec, pro drug developer. Amateur everything else: COOKING, ferments, preserving, charcuterie, fishing, gardening, weightlifting, BIRDER, photography, physics, literature, writer, history, DAD
Color wheel test was fascinating
August 17, 2025 at 9:18 PM
Color wheel test was fascinating
target prosecution like this bispecific is a delicate dance between hoped-for efficacy and avoided toxicity ... the EGFRxHER3 pair is a good choice. Why? see here ... sugarconebiotech.com/insights/tar...
Targeting HER3 – a little wave of drug development that’s about to get a lot bigger — SugarCone Biotech
A post-ASCO update on tumor targets DLL3, B7H3 and HER3 July 2025 Paul D Rennert, SugarCone Biotech LLC Introduction: DLL3, B7H3 and HER3 are compelling tumor antigens to target with cancer therapeutics. They have interesting patterns of expression in different cancer indications; thus, diverse t
sugarconebiotech.com
August 15, 2025 at 6:04 PM
target prosecution like this bispecific is a delicate dance between hoped-for efficacy and avoided toxicity ... the EGFRxHER3 pair is a good choice. Why? see here ... sugarconebiotech.com/insights/tar...
reminds me to share a landscape peak into advanced therapies - CAR-T and bispecifics - in the autoimmune and inflammation space
July 22, 2025 at 11:57 AM
reminds me to share a landscape peak into advanced therapies - CAR-T and bispecifics - in the autoimmune and inflammation space
Last Boat to Tangier
May 11, 2025 at 12:03 PM
Last Boat to Tangier
and here's a bispecific landscape update from the analysts at sugarconebiotech.com
April 17, 2025 at 5:19 PM
and here's a bispecific landscape update from the analysts at sugarconebiotech.com